BOO O, 14: 125 133, 2002

ANAKOHH

A
*
K. X
, ,
*E H K, 2 M 2002

. o o oo o o oo o o o,
oo o o. O 2-
o o o oo o. o o, -o, o o oo
. O o o o o o
o . o, 5 , o . o o o o o o o oo o o o o o o o o.
-: ,
Haidopoulou K. Pharmacological treatment of asthma in children. D Pediatric Department
AXEPA Hospital, Thessaloniki. Paediatr N Gr 2002, 14: 125 - 133.
The current concept of asthma therapy is based on a stepwise approach, depending on disease severity,
and its aim is to reduce the symptoms that result from airway obstruction and inflammation, to prevent
exacerbations and to maintain normal lung function. 2-adrenoreceptor agonists and corticosteroids are at
present the most effective drugs for the treatment of airway obstruction and inflammation, with leukotriene
receptor antagonists, theophylline and anticholinergics as second or third line therapy. New approaches to
asthma therapy recommend drug combinations. Treating asthma in children younger than 5 years old is
challenging because there are few reports on safety and doses in these ages. On-going research in asthma
is advancing -especially in fields of immunology and genetics- and opens doors to new treatment modalities
and possibly curative therapeutic approaches.
Key words: antiasthmatic therapy, childhood asthma

o o o o o o
oo o . o o )

oo (ooo o ) ) o (o o o oo o o ).

125

126

BOO O, 14, 2

o o
oo ( o ). o o o
o
o1 o ,
oo o
o o
o o o o2. ,
o o . O o o o o o
(oo ) oo o o (meter-dose inhaler, MDI). ooo o o o o o o oo (Aerochamber, Babyhaler, Volumatic ). O o
(Diskhaler, Turbohaler
) ooo o o
oo o
o o o (dry-powder inhaler, DPI).
5 , o oo MDI. <5 ooo oo
MDI. O oo o , o
o o o o
o o .
o
o o 3. , o ,
o o
oo o o4.

oo
2-: oo o
o o
o o 1960
5. O 2-oo o
o o o
o o, o o o 2-6. O 2- oo ooo o
o oo c-AMP oo o o o7.

o o ooo oo o o
o: o 2- (o 4-6
) (o, o, o) o 2- (9-12 ) (, oo)8. o o o o o
oo o, ooo o .
O 2- oo o
o ( o 5 )9 o
o. o o o
o o
o10. ,
2-
o o o11.
O 2- ,
ooo o o o oo o o oo
12.
oo o ooo oo, o 2 oo o o
. o
o13, o
o oo 14.
o. o o oo o o o o oo o oo oo15. oo o o16 o o
o oo o o ,
o oo o o o 2- 7,17. o o o o, o o o o o o.
o o
o 2- 12. o
o o
2- . o o ooo o
oo18 oo,

 B , 14, 2

o o o o o .
o. o o oo o oo19,20. o o 12. o oo o 2-
o oo, o o o o ooo ooo oo o o7. o,
o 12 oo
oo 21.
o. o o
o 22. o o o oo o 2 o o o o.
oo. oo o o (o o o, o
o VIP, o , o oo o o o)
o 23.

o
o
o o o (, o o).
o. o
24. o o o
oo ooo o o o o o o. o oo o o o25. oooo o o . oo .
o (o,
o .). o o o o o o 7 o
-

127

. , o o o o
o 12: )
(3-10 ) o oo o ) o
o
oo .
o o oo oo
9. o o o o
o o 7
o o o , o o 7
o oo
. o
o oo 10-14 10.
o (oo, o, oo, o). o o

oo o 10.
o, o
o o o . O o
o o o ( o o
oo o o ). O o (, , o ) o o o26.
o o
CAMP27, o oo o
o (oo). o o o 1,1 cm o o o , o o, o oo o o o
oo. o o
o o oo o o o o
oo
. o o o
oo28.
o o
, o o o. o, o o o -

128

B , 14, 2

5 29. ,
o o
, o
: oo,
o o o,
(<200 mcg oo o, <350
mcg o 500-750 mcg oo), o o
o o o 14. ,
o
o oo o o o oo 30.
o o
o . o12 o o o o o oo o
ooo o . oo o o o
o
31 o o oo o o21. oo o o o 32.

o o
(o o, o). o oo o ooo o oo
. oo
o 33, o
.
o (o). o
o o
o o oo , o o o
oo o
o o5.
-o. O o o o,
o oo
o o
oo 34. -o-

oo o . o o
o o o o 5-o (zileuton) o oo (oo, o, o).
o o o o o o-o
oo , o o ( o )35-37. o o 38. oo o o o oo o, oo 32.

o o o

o o. o
o : o o, o oo, o oo oo

, o o o
o oo
(. 1)14.
5 oo o o
o o o 39.
o o o: ) o o 2-
o ooo o o )
( o,
, -o ) o oo o o o oo .
o o
(. 1)32:
o o : 2- o . o .
o oo : o o , o
, -o40,41, o. o oo o
-o .
o oo .

 B , 14, 2

129

1. o o o o o
.

o 4
oo
o 3
o oo
o 2
o oo
o 1
o o

>30%

> 1 / o.

>60%-<80%

>30%

> 2 /

80%

20-30%

2 /

80%

<20%

>2 o/o

2 o/o

+ 2 :
2-


-

+ 1 :


-

: 0

:
2-

E. 1.
.

o . o
o o
- 2- . o o o o -oo42,43,44, o.
oo . o 2- . , o -o o
o o -

o
FEV1 PEFR

PEFR
60%

+
(- )

. O o
o o o o o .

o o
o , o o o o o,
oo o .
ooo o o

oo o (step-down). o oo o ooo o 3 .
o, o
o o
(step-up). o o o o o o,
2- .
o o
o
o oo o o o o
(. 2).
o / oo o oo o oo o o o o o o . , o o o o
o
o o

130

B , 14, 2

2. o

1. O o
o.
2. O oo
.
3. o o
o oo ( , o)
4. o ( o)
5. ( )

o
oo o.

o o o o
o o o oo.
o o o o o o o o o
oo o. O oo o o o o
o o45. , 5-10
o 20-30 . o o o o
o oo . o,
o o o o o o oo oo .
o
o
. O o
oo 12: ) o 2-
o (
). o 2-3
o >80%
) o oo o
o o (
o o 2 ) ) o 2- 46. o

10-12 o o o
) oo7,33. o
o , o o .

o
. o o
oo o o o o
oo o47.
o, o oo o o
o ,
ooo. o
o oo
oo o o.
o o o
o oo o (oo, o, o ..).
o
o (. 2). o o o o o o oooo 48. o o
2- o (2-4
puffs o, 20 , o o 3
).
o o oo
oo (, , ). o
oo o . , o 2- ( 2-3 24-48
). o
oo o.
, o 2-
o ( o ) o (o 0,5-1/mg/kg o o
oo32), o .
. oo 2- o

 B , 14, 2

131

:
2- :
2-4 puffs (MDI) / 20

Wheezing:
:
PEFR > 80%

Wheezing:
:
PEFR 50-80%

Wheezing:
:
PEFR 50-80%

2-
3-4

0,5-1 mg/kg

2-
3-4

0,5-1 mg/kg

2-

E. 2. A .

o
. o o o
(. 3).
o oooo o oo (o 6-8 L/min) o49, o 2-
( o 5 mg/ml 0,03 ml/
kg, o 0,25 ml o 1 ml) 20 1 , o oo
( 250 g/ml 0,5-1 ml)
o o 2-
oo o (1-2 mg/kg o o
40 mg32). o o
o oo (0,01 ml/kg).
o, o o o
oo oo50.

3. o o o

Io o
o o o o
2 o ooo o
o o
o ooo o / o o oooo.
o
o o o
(>2 /)
2-
o
o o
o o o
o o
o o ( o,
ooo )
oo o o o
ooooo o
o o

132

B , 14, 2

o o o
oo IgE, o h-2 o
(-IL4, -IL13), o oo o (-IL1, -TNF),
o o o (IL-10,IL-12), o o o o
o o oo
o oo51, o o
.
, o o oo o o o
oo o,
o o
oo . o, o o o oo o
52. oo o o o o o o o.

o
1 Newhouse MT, Dolovich MB. Control of asthma by aerosols. N Eng J Med 1986, 315: 870-4.
2. Cole CH. Special problems in aerosol delivery: neonatal
and pediatric considerations. Respir Care 2000, 45:
646-51.
3. Child F, Davies S, Clayton S, Fryer A, Lenney W. Inhaler
devices for asthma: do we follow the guidelines; Arch
Dis Child 2002, 86: 176-9.

Tract in Children. 6th ed. Philadelphia: WB Saunders;

1998: 688-730.
11. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonist and the risk of death and near death from asthma.
N Eng J Med 1992, 326: 501-6.
12. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the diagnosis and
management of asthma. Publication No 97-4051.
Bethesda MD, 1997.
13. Politiek M, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in metacholineinduced severe bronchocostriction. Eur Respir J 1999,
13: 988-92.
14. Global strategy for asthma management and prevention.
NHLBI/WHO Workshop Report. National Institutes of
Health, National Heart, Lungand Blood Institute.
Bethesda MD, 1995.
15. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic
bronchodilators. Am Rev Respir Dis 1984, 129: 856-70.
16. Craven D, Kercsmar MC, Myers RT, O Riordan MA, Golonka G, Moore S. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr 2001, 138: 51-8.
17. , o , , o
. o o o o oo o
o . oo o 1993, 5: 238-41.
18. Pauels RA, Buist AS, Calverlay PM, Jenkins CR, Hurd SS.
Global Strategy for the diagnosis, management and
prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am
J Respir Crit Care Med 2001; 163: 1256-76.
19. Wenberger M, Hendeles L. Theophylline in asthma. N
Engl J Med 1996, 334: 1380-8.

4. Kamps AW, van Ewijk B, Roorda RJ. Poor inhalation technique, even after inhalation instructions in children
with asthma. Pediatr Pulmonol 2000, 29: 39-42.

20. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth
muscle relaxants. Eur Respir J 1995, 8: 637-42.

5. Person C. On the history of the sympathomimetics in asthma. In: Pauels R, O Byrne P, eds. Lung Biology in
Health and Disease. Beta2-agonists in asthma treatment. New York:michale Dekker, Inc; 1997: 1-18.

21. Karlsson JA. Theophylline: anti-inflammatory effects. In:

Leff AR, editor. Pulmonary and critical care pharmacology and therapeutics. USA,McGrew-Hill, 1996,
609-20.

6. Barnes PJ. Beta adrenergic receptors and their regulation.

Am J Respir Crit Care Med 1995, 152: 838-60.

22. Camargo CA. Grand Seminar: Optimizing therapy for

acute asthma. Program and abstracts of the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology; March 16-21, 2001, New
Orleans, Louisiana.

7. Rabe FK, Schmidt DT. Pharmacological treatment of asthma today. Eur Respir J 2001, 18(Suppl 34): 34s-40s.
8. . O o 2- o oo o.
2001, 64: 342-6.
9. Lipworth BJ, Clark RA, Dhillon DP, Brown RA, McDevitt
DG. Beta-adrenoreceptor responses to high doses of
inhaled salbutamol in patients with bronchial asthma.
Br J Clin Pharmacol 1988, 26: 527-33.
10. Kercsmar MC. Athma. In: Chernick V, Boat TF and
Kendig EL eds. Kendigs Disorders of the Respiratory

23. Barnes PJ. New treatments for asthma. Eur J Int Med
2000, 11: 9-20.
24. Cockroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen induced early astmatic responses and increased bronchial responsiveness
to histamine. J Allergy Clin Immunol 1987, 79: 734-40.
25. Barnes PJ, Adcock IM. NF-kB: a pivotal role in asthma

 B , 14, 2

and a new target for therapy. Trends Pharmacol Sci

1997, 18: 46-50.
26. Barnes PJ. Inhaled corticosteroids for asthma. N Engl J
Med 1995; 332: 868-875.
27. The Childhood Asthma Management Program Research
Group. Longterm effects of budesonide or nedochromil in children with asthma. N Engl J Med 2000, 343:
1054-63.
28. Agertroft L, Pedersen S. Effect of long treatment with
budesonide on adult height in children with asthma. N
Engl J Med 2000, 343: 1064-9.
29. Turktas I, Ozkaya O, Bostanci I, Bideci A, Cinaz P. Safety
of inhaled corticosteroid therapy in young children
with asthma. Ann Allergy Asthma Immunol 2001, 86:
649-54.
30. Taylor DA, Jensen MW, Kanabar V. A dose dependent
effect of the novel inhaled corticosteroid ciclesonide
on airway responsiveness to adenosine-5-monophosphate in asthmatic patients. Am J Respir Crit Care
Med 1999, 160: 237-43.
31. Gibson PG, Saltos N, Fakes K. cute anti-inflammatory
effects of inhaled budesonide in asthma: a randomized
controlled trial. Am J Respir Crit Care Med 2001, 163:
32-6.
32. Global strategy for asthma management and prevention
revised. NHLBI/WHO Workshop Report: Global Strategy for asthma. NIH Publication No 02-3659, 2002.
33. Wettengel R, Berdel D, Hoffmann D. Asthmatherapie bei
Kindern und Erwachsenen. Empfelungen der Deutchen Atemwestliga in der Deutschen Gesellschaft fr
Pneumonologie. Med Klin 1998, 93: 639-50.
34. Roquet A, Dahlen B, Kumlin M. Combined antagonism
of leukotrienes and histamine produces predominant
inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care
Med 1997, 155: 1856-63.
35. Drazen JM, Israel E, O Byrne PM. Treatment of asthma
with drugs modifying the leukotriene pathway. N Engl
J Med 1999, 340: 197-206.
36. Skoner DP. Balancing safety and efficacy in pediatric
asthma management. Pediatrics 2002, 109: 381-92.
37. Kelly W, Bisgaard H. Leukotriene modifiers. Pediatrics
2002; 109: 170-1.
38. Dockhorn R, Baumgartner R, Leff J. Comparison of the
effects of intravenous and oral montelucast on airway
function: doubleblind, placebo controlled, three period crossover study in asthmatic patients. Thorax
2000, 55: 260-5.
39. oo . o o o
. oo & ooo 2001, 9: 141-9.
40. Malmstrom K, Rodriguez-Gomez G, Guerra J. Oral montelucast, inhaled beclomethasone, and placebo for

133

chronic asthma. Ann Intern Med 1999, 130: 487-95.

41. Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in
patients with mild to moderate asthma: an intergrated
analysis of zafirlucast trials. Thorax 2000, 55: 478-83.
42. Castro M. Controversies in asthma therapy: Leukotriene
modifiers as an add-on therapy. Programm and abstracts of CHEST 2001: 67th Annual Scientific Assembly of the American College of Chest Physicians.
November 4-8, 2001; Philadelphia, Pensylvania.
43. Laviolette M, Malmstrom K, Lu S. Montelucast added to
inhaled beclomethasone in treatment of asthma. Am J
Respir Crit Care Med 1999, 160: 1860-2.
44. Lofdahl CG, Reiss TF, Leff Ja. Randomised, placebo
controlled trial of effect of a leukotriene receptor antagonist, montelucast, on tapering inhaled corticosteroids in ansthmatic patients. BMJ 1999, 319: 87-90.
45. Mc Fadden ER Jr, Gilbert IA. Exercise induced asthma.
N Engl J Med 1994, 330: 1362-7.
46. Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER, Van As
A. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care
Med 1994, 150: 1612-5.
47. Weinberger MM. What are the problems with the NIH
Guidelines? What are the solutions? Proceedings of
the fourth International Congress on Pediatric Pulmonology; 2000: 21-24 February; Nice. France. EDK
Paris; 2000: 16.
48. Warman LK. Management of asthma exacerbations:
Home treatment. J Asthma 2000, 37: 461-8.
49. Inwald D, Roland M, Kuitert L, McKenzie SA, Petros A.
Education and debate: oxygen treatment for acute severe asthma. BMJ 2001, 323: 98-100.
50. oo , o . oo o o o o o oooo. 1998, 61: 59-69.
51. Barnes PJ. Cytokines as novel therapies for airway disease. Eur Resp J 2001, 18(suppl): 67S-77S.
52. Spahn JD, Szefler JS. Childhood asthma: New insights
into management. J Allergy Clin Immunol 2002, 3-13.

:
.
. . 76
546 42
e-mail: haidoka@med.auth.gr
Corresponding author:
K. aidopoulou
76, L. K. Karamanli
546 42 Thessaloniki
e-mail: haidoka@med.auth.gr